Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

The advent of sodium-glucose cotransporter 2 (SGLT2) inhibitors represents a major advance for people with type 2 diabetes (T2DM) and chronic kidney disease (CKD). The results of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial have cle...

Descripción completa

Detalles Bibliográficos
Autores principales: Neuen, Brendon L, Jardine, Meg J, Perkovic, Vlado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993192/
https://www.ncbi.nlm.nih.gov/pubmed/32003833
http://dx.doi.org/10.1093/ndt/gfz252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993192/
https://www.ncbi.nlm.nih.gov/pubmed/32003833
http://dx.doi.org/10.1093/ndt/gfz252

Ejemplares similares